EVOFEM BIOSCIENCE INC - EVFM STOCK NEWS

Evofem Biosciences (OTCQB: EVFM) has secured voting agreements with Series E-1 stockholders and convertible noteholders to support its proposed merger with Aditxt's subsidiary Adifem. This follows Aditxt's recent $2.28 million investment in Evofem through Series F-1 convertible preferred stock, completing their total $5.0 million commitment since May 2024. The merger's closing conditions include majority shareholder approval and Aditxt raising approximately $17 million, with $15.2 million needed to satisfy Evofem's senior secured noteholder. The capital received has enabled Evofem to acquire SOLOSEC® and support Phexxi® initiatives targeting GLP-1 users.

Aditxt (NASDAQ: ADTX) has announced a virtual fireside chat on October 28, 2024, at 11:30 AM ET, featuring Aditxt CEO Amro Albanna, Evofem CEO Saundra Pelletier, and moderated by Dr. Drew Pinsky. The event will focus on:

• Aditxt's acquisition of Evofem
• Post-acquisition plans for Evofem
• Aditxt's approach to accelerating innovations

The chat will highlight Evofem's evolution into a multi-product women's health franchise, including the re-launch of Solosec® and the planned launch of the Mitomic Endometriosis Test (MET™) in mid-2025. Aditxt estimates it will require $19.3 million to fund the Evofem acquisition, including $1.8 million for merger consideration and $2.28 million for additional Evofem stock purchase by October 31, 2024. An additional $15.2 million is needed to satisfy Evofem's Senior Secured Note at closing.

Aditxt (NASDAQ: ADTX) has completed the Third Parent Equity Investment in Evofem Biosciences (OTCQB: EVFM) under their Amended and Restated Merger Agreement. Aditxt purchased 460 shares of Evofem Series F-1 Convertible Preferred Stock for $460,000, bringing their total investment to $1.72 million. Aditxt plans to complete the Fourth Parent Equity Investment of $2.28 million by October 31, 2024.

Evofem has expanded from a single-product company to offering diversified solutions in women's health, including Phexxi (contraceptive gel) and SOLOSEC (antibiotic). They are preparing to launch the Mitomic Endometriosis Test in mid-2025 and have signed a licensing agreement with Pharma 1 Drug Store to bring Phexxi to the Gulf Cooperation Council region.

Aditxt aims to accelerate innovative health companies through its business platform, which includes subsidiaries Adimune (immune health) and Pearsanta (precision health). Both companies believe the merger will strengthen Evofem's ability to expand access to women's health products globally.

Aditxt, Inc. (NASDAQ: ADTX) announced that its acquisition target, Evofem Biosciences, Inc. (OTCQB: EVFM), has filed a preliminary proxy to seek stockholder approval for the merger outlined in the Amended and Restated Merger Agreement dated July 12, 2024. The agreement involves Adifem, Inc., a wholly-owned subsidiary of Aditxt, merging with Evofem, resulting in Evofem becoming a wholly-owned subsidiary of Aditxt.

The companies are targeting to close the transaction in the fourth quarter of 2024, subject to Evofem stockholder approval and other closing conditions, including Aditxt raising sufficient capital to fund its obligations at closing. However, no assurance is provided that all conditions will be met or that the transaction will ultimately close.

Aditxt, Inc. (NASDAQ: ADTX) announced that its subsidiary, Pearsanta, has entered into a collaboration agreement with Evofem Biosciences for the U.S. launch of a blood-based diagnostic test for endometriosis in mid-2025. The Mitomic® Endometriosis Test (MET™) detects a specific deletion in mitochondrial DNA, a novel biomarker for endometriosis.

Endometriosis affects approximately 190 million women worldwide, with no current validated blood-based tests available. The collaboration aims to develop a go-to-market strategy and commercial plan for MET. Over 300 endometriosis cases have been evaluated using MET, with 600 planned for clinical validation.

This partnership aligns with Evofem's strategy to expand its women's health product offerings and Aditxt's goal of accelerating healthcare innovations. The collaboration may also lead to future tests, such as early detection of ovarian cancer.

Aditxt (NASDAQ: ADTX) and Evofem Biosciences (OTCQB: EVFM) have signed a Second Amendment to their merger agreement, extending the timeline for Aditxt's $3 million funding to Evofem. The acquisition is now targeted to close in Q4 2024. Evofem aims to grow revenue through its three-pronged strategy: increasing U.S. sales of Phexxi® and SOLOSEC®, expanding its portfolio, and pursuing international partnerships. Aditxt plans to introduce four health-focused programs, including women's health through the Evofem merger. The deal's completion depends on shareholder approvals and Aditxt securing sufficient capital.

Evofem Biosciences (OTCQB: EVFM) is addressing concerns about the impact of GLP-1 receptor agonists on oral contraceptive effectiveness. These medications, used for obesity and type 2 diabetes treatment, can cause gastrointestinal side effects that may reduce oral contraceptive absorption. Evofem offers Phexxi, a hormone-free, on-demand contraceptive gel, as a non-oral alternative.

Phexxi maintains the vagina's acidic pH, creating an environment inhospitable to sperm. It's particularly suitable for women using GLP-1 medications who are concerned about potential drug interactions affecting their birth control efficacy. Evofem's CEO, Saundra Pelletier, emphasizes the importance of understanding these interactions and providing alternative contraceptive options for women managing chronic conditions like obesity and diabetes.

Evofem Biosciences reported financial results for Q2 2024, showing significant improvements:

- Net product sales increased 69% to $4.2 million
- Operating loss improved 81% to $1.4 million
- Total operating expenses decreased 43% to $5.5 million

Key developments include:
- Acquisition of global rights to SOLOSEC, a single-dose antibiotic for sexual health infections
- Licensing of Phexxi commercial rights in the Middle East
- Partnership with Hello Alpha to offer Phexxi as hormone-free contraception
- 7.4% lower rebate on Phexxi prescriptions to Medi-Cal
- Issuance of fifth U.S. patent for Phexxi

The company received $2.0 million from Aditxt, Inc. to reinstate the Merger Agreement and through preferred stock sale.

Evofem Biosciences (OTCQB: EVFM) has signed a License and Supply Agreement with Pharma 1 Drug Store for the Middle East rights to Phexxi, its FDA-approved hormone-free contraceptive. Pharma 1 will have exclusive commercialization rights in several Middle Eastern countries, including the UAE, Kuwait, Saudi Arabia, and Qatar. The company plans to file for regulatory approval in the UAE in Q3 2024.

The UAE contraceptive drug market is projected to reach $185.1 million by 2030. This agreement aligns with Evofem's strategy to expand and diversify its revenue stream. Phexxi is the first and only locally-acting contraceptive gel approved by the FDA, applied before intercourse to maintain a vaginal pH inhospitable to sperm and certain pathogens.